|1.||Singh, Udai P: 3 articles (01/2014 - 01/2009)|
|2.||Saris, W H M: 3 articles (03/2006 - 04/2002)|
|3.||Westerterp-Plantenga, Margriet S: 3 articles (04/2004 - 04/2003)|
|4.||Hukshorn, Chris J: 3 articles (04/2004 - 04/2003)|
|5.||Saris, Wim H M: 3 articles (04/2004 - 04/2003)|
|6.||Westerterp-Plantenga, M S: 3 articles (12/2003 - 11/2000)|
|7.||Hukshorn, C J: 3 articles (12/2003 - 11/2000)|
|8.||Mak, Robert H: 2 articles (12/2014 - 01/2014)|
|9.||Cheung, Wai W: 2 articles (12/2014 - 01/2014)|
|10.||Gertler, Arieh: 2 articles (12/2014 - 01/2014)|
12/01/2014 - "Pegylated leptin antagonist treatment ameliorates CKD-associated cachexia in mice. "
01/01/2014 - "A pegylated leptin antagonist ameliorates CKD-associated cachexia in mice."
01/01/2014 - "We tested whether treatment with a pegylated leptin receptor antagonist (PLA) attenuates cachexia in mice with CKD. "
|2.||Body Weight (Weight, Body)
12/01/2003 - "Although treatment with PEG-OB protein led to a greater body weight loss relative to placebo, weight maintenance thereafter was mainly supported by dietary restraint, which was more effective in the placebo-treated group, resulting in a slower regain of body weight."
12/01/2003 - "Body weight regain was inversely correlated with the increase in cognitive dietary restraint during treatment (PEG-OB group: r(2)=0.49, P<0.02; placebo group: r(2)=0.60, P=0.01). "
12/01/2003 - "During 8 weeks follow-up, body weight increase was larger in the PEG-OB group compared to placebo (P<0.05), and body weight regain was faster. "
04/01/2011 - "These findings indicate that PEG-OB(1-23) is an OB(1-23) analog with significantly enhanced stability and suggest that obestatin could play a role in modulating physiological lipid metabolism, although it does not appear to be involved in regulation of food/fluid intake, body weight or fat deposition."
11/01/2000 - "Percent change in serum triglycerides from baseline was significantly correlated with body weight loss in the PEG-OB group, but not in the placebo group. "
|3.||Weight Loss (Weight Reduction)
04/01/2002 - "At the end of the study no significant differences in the delta or percentage weight loss between the placebo (n = 14) and PEG-OB (n = 14) groups was observed. "
12/01/2003 - "With PEG-OB treatment, additional weight loss (P<0.03) was observed. "
06/01/2003 - "Weekly subcutaneous administration of PEG-OB led to significant additional weight loss (2.8 kg) but it did not reverse the fasting-induced changes in the thyroid, corticotropic, somatotropic axes and sympathetic nervous system activity. "
04/01/2003 - "Compared with placebo treatment, treatment with PEG-OB led to significant (P < 0.03) additional weight loss (14.6 +/- 0.8 compared with 11.8 +/- 0.9 kg) and a reduction in appetite (P < 0.05) after 46 d, but the 2 treatment groups did not differ significantly in changes in body composition, energy expenditure, and metabolic variables. "
04/01/2002 - "Weekly injection of 60 mg PEG-OB did not lead to additional weight loss after 8 weeks of treatment. "
03/01/2005 - "A role for high leptin levels in the proinflammatory state associated with obesity has been proposed on the basis of observational studies, but a recent interventional study employing administration of long-acting pegylated leptin resulting in very high pharmacologic levels in obese subjects did not support this idea. "
04/01/2004 - "Although PEG-OB treatment significantly increased weight loss (P < 0.03), the data do not support a proinflammatory role of leptin in human obesity."
01/31/2014 - "Finally, intralesional injections of a pegylated leptin receptor (Ob-R) antagonist or of an inhibitor of Janus kinase2, which transduces the Ob-R signal, markedly attenuated pain in the endometriosis model. "
02/01/2008 - "Findings of this study show that the disruption of leptin signaling by ip injection of the pegylated leptin peptide receptor antagonist (LPrA) impairs the establishment of endometriosis-like lesions (derived from uteri of C57BL/6 female siblings) and results in a reduction of viable organized glandular epithelium, vascular endothelial growth factor-A expression, and mitotic activity. "
|2.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|3.||Peptide Receptors (Peptide Receptor)
|6.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|7.||Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
|8.||von Willebrand Factor
|9.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)